Zai Lab Limited Announces Closing of U.S. Initial Public Offering of ADSs
Wednesday, 27 September 2017｜Source：CHINA CHAMBER OF COMMERCEFOR IMPORT&EXPORT OF MEDICINES &HEALTH PRODUCTS｜Author：
NEW YORK, Sept. 22, 2017 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) announces the closing of its U.S. initial public offering of 9,583,333 American depositary shares (“ADSs”) at a price of US$18.00 per ADS, which includes the 1,250,000 shares sold upon full exercise of the underwriters’ option to purchase additional ADSs (the “IPO”), raising gross proceeds of approximately US$172.5 million. The ADSs have been approved for listing on the Nasdaq Global Market and began trading on September 20, 2017 under the ticker symbol “ZLAB.”
J.P. Morgan, Citigroup and Leerink Partners acted as joint book-running managers for the IPO.
About Zai Lab
Zai Lab (NASDAQ: ZLAB) is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. The company’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast growing segments of China’s pharmaceutical market and global unmet medical needs. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partner’s and its own products in order to impact human health worldwide.
